Tesamorelin + Ipamorelin research monograph — the dual-pathway GH-axis blend
This product is a fixed-ratio blend of two growth-hormone-axis peptides, each with its own VialTalk monograph: Tesamorelin (a GHRH analogue) and Ipamorelin (a selective ghrelin-receptor agonist / GHRP). The research interest in combining them is a well-described physiological synergy — pairing a GHRH with a GHRP produces a larger growth-hormone pulse than either produces alone. This monograph summarises the two components, the dual-pathway rationale, the genuinely strong single-agent evidence for Tesamorelin, and the important fact that the combination itself has not been tested in controlled trials.
Chemical identity and structure.
The blend contains two distinct peptides at a fixed ratio. Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH). Ipamorelin is a selective pentapeptide ghrelin-receptor agonist. There is no single formula or molecular weight for the blend; each peptide retains its own identity and pharmacokinetics. See the individual VialTalk monographs for per-compound chemistry.
Mechanism of action.
The two components drive GH release through two different receptors, and that is the whole point. Tesamorelin activates GHRH receptors on anterior-pituitary somatotrophs, increasing the amplitude of GH pulses — the amount released per secretory event — without much changing pulse frequency. Ipamorelin activates the ghrelin receptor, increasing pulse frequency, and is "selective" in the sense that it raises GH with minimal effect on cortisol, prolactin, or hunger (a contrast with older GHRPs). Co-activating both pathways produces a synergistic GH pulse: the endocrinology literature reports GH secretion several-fold higher (commonly cited as roughly 2–5×) when a GHRH analogue and a ghrelin agonist are given together than with either alone.
Research applications and the evidence base.
The two components are not equally evidenced, and the blend is less evidenced than either. Tesamorelin has robust human clinical data — it is studied (and approved in the HIV-associated lipodystrophy setting) for reducing visceral adipose tissue, with reported visceral-fat reductions in the mid-teens percent and modest lean-mass gains. Ipamorelin's evidence is largely preclinical and early-stage. Critically, there are no published controlled trials of Tesamorelin and Ipamorelin administered together as a fixed blend; every combination figure is extrapolated from the single-agent data plus the general GHRH/GHRP synergy literature. Present the combination as mechanistically motivated, not as clinically validated.
Community protocol information.
The blend is sold at a fixed milligram ratio (a commonly cited example is Tesamorelin in the 1–2 mg range with Ipamorelin in the ~100–300 mcg range), reconstituted with bacteriostatic water for subcutaneous use; community protocols report once-daily or AM/PM dosing, frequently 5 days on / 2 days off, and cycles such as 8 weeks on / 8 weeks off, with explicit caution about receptor desensitisation and IGF-1 drift beyond roughly 12 weeks of continuous use. Blend note: as with any fixed-ratio blend, the two components cannot be titrated independently, no controlled PK/interaction data exist for the specific combination, and these figures are community practice extrapolated from single-agent protocols — research context only, not clinical recommendations. Read alongside the individual Tesamorelin and Ipamorelin monographs.
Stack combinations researchers commonly use.
The product is itself a GHRH+GHRP stack. Community discussion sometimes adds CJC-1295 (another GHRH-axis agent) or pairs the GH-axis blend with recovery/repair peptides such as MGF or IGF-1 LR3 in body-composition and recovery research framing. The combination evidence is preliminary.
Storage and handling.
Store the lyophilized blend frozen (−20 °C). After reconstitution, refrigerate at 2–8 °C and use within roughly two to four weeks; do not freeze the reconstituted solution. As with any blend, default to the more conservative stability window of the two components.
Quality and COA considerations.
A meaningful COA should confirm identity by mass spectrometry for both peptides, report purity by HPLC, and report the ratio of Tesamorelin to Ipamorelin rather than a single total mass — without the ratio you cannot know the actual dose of each. Endotoxin should be reported for injection or tissue-contact models.
Research-use note: This monograph is an educational summary of the published research literature and community-reported protocols for the Tesamorelin + Ipamorelin blend and its individual components. It is for laboratory and research use only. Tesamorelin has substantial single-agent human data; the fixed combination does not; blend dosing is more variable and less studied than single-compound dosing; none of the figures above is a therapy or a usage recommendation; and nothing here is medical advice.